Sanofi SA

Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant

07 Dec 2023 01:35:00 By Nasdaq GlobeNewswire

Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology

06 Dec 2023 21:30:00 By Nasdaq GlobeNewswire

Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease

27 Nov 2023 01:30:00 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - October 2023

23 Nov 2023 12:00:00 By Nasdaq GlobeNewswire

Press Release: Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results

27 Oct 2023 01:31:00 By Nasdaq GlobeNewswire

Press Release: Sanofi Enters Next Chapter of Play to Win Strategy

27 Oct 2023 01:30:00 By Nasdaq GlobeNewswire

Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)

22 Oct 2023 15:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio

19 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The NEJM

18 Oct 2023 04:45:00 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - September 2023

17 Oct 2023 14:18:26 By Nasdaq GlobeNewswire

Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis

13 Oct 2023 10:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment

04 Oct 2023 01:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment

04 Oct 2023 01:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli

03 Oct 2023 01:30:00 By Nasdaq GlobeNewswire

Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review

26 Sep 2023 01:30:00 By Nasdaq GlobeNewswire

Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A

25 Sep 2023 03:00:00 By Nasdaq GlobeNewswire

Press Release: Availability of the Q3 2023 Memorandum for modelling purposes

22 Sep 2023 01:30:00 By Nasdaq GlobeNewswire

Press Release: Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change

19 Sep 2023 02:30:00 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - August 2023

11 Sep 2023 14:02:14 By Nasdaq GlobeNewswire

Press Release: Sanofi announces changes to its Executive Committee

31 Aug 2023 01:30:00 By Nasdaq GlobeNewswire